APA

Ozaki T., Nakamura M., Ogata T., Sang M., Yoda H., Hiraoka K., Sang M. & Shimozato O. (20180221). Depletion of pro-oncogenic RUNX2 enhances gemcitabine (GEM) sensitivity of p53-mutated pancreatic cancer Panc-1 cells through the induction of pro-apoptotic TAp63. : Oncotarget.

Chicago

Ozaki Toshinori, Nakamura Mizuyo, Ogata Takehiro, Sang Meijie, Yoda Hiroyuki, Hiraoka Kiriko, Sang Meixiang and Shimozato Osamu. 20180221. Depletion of pro-oncogenic RUNX2 enhances gemcitabine (GEM) sensitivity of p53-mutated pancreatic cancer Panc-1 cells through the induction of pro-apoptotic TAp63. : Oncotarget.

Harvard

Ozaki T., Nakamura M., Ogata T., Sang M., Yoda H., Hiraoka K., Sang M. and Shimozato O. (20180221). Depletion of pro-oncogenic RUNX2 enhances gemcitabine (GEM) sensitivity of p53-mutated pancreatic cancer Panc-1 cells through the induction of pro-apoptotic TAp63. : Oncotarget.

MLA

Ozaki Toshinori, Nakamura Mizuyo, Ogata Takehiro, Sang Meijie, Yoda Hiroyuki, Hiraoka Kiriko, Sang Meixiang and Shimozato Osamu. Depletion of pro-oncogenic RUNX2 enhances gemcitabine (GEM) sensitivity of p53-mutated pancreatic cancer Panc-1 cells through the induction of pro-apoptotic TAp63. : Oncotarget. 20180221.